Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. https://t.co/YzezGLwsAB
Alemtuzumab versus interferon beta 1a for relapsing-remitting #multiplesclerosis https://t.co/0CtUSmFNg0 https://t.co/dW3hSBdtvv
Cochrane review on alemtuzumab versus interferon beta 1a for relapsing-remitting #MS available at: https://t.co/ynIwx2AP4U
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. - PubMed - NCBI https://t.co/YIMYfSFilF
RT @CochraneLibrary: Low- to moderate-quality #CochraneEvidence that annual #IV cycles of alemtuzumab may reduce proportion of participants…
Alemtuzumab versus interferón beta 1a para la esclerosis múltiple remitente recidivante, revisión Cochrane. https://t.co/dwTHcrChu1
RT @CochraneLibrary: Low- to moderate-quality #CochraneEvidence that annual #IV cycles of alemtuzumab may reduce proportion of participants…
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. - PubMed - NCBI https://t.co/4MEAK0mSGr
(Cochrane) Alemtuzumab, posible alternativa a interferón en esclerosis múltiple remitente recurrente https://t.co/1oYefpBQ92
RT @evidpediatria: Alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis https://t.co/v8pFYiWdG5 via @CochraneUK
Alemtuzumab, a humanised monoclonal antibody, as possible alternative therapy to interferon… https://t.co/PTFaW8pVMb
RT @evidpediatria: Alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis https://t.co/v8pFYiWdG5 via @CochraneUK
Alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis https://t.co/v8pFYiWdG5 via @CochraneUK
RT @cochranecollab: RT @CochraneLibrary: Low- to moderate-quality #CochraneEvidence that annual #IV cycles of alemtuzumab may reduce propor…
RT @CochraneLibrary: Low- to moderate-quality #CochraneEvidence that annual #IV cycles of alemtuzumab may reduce proportion of participants…
RT @cochranecollab: RT @CochraneLibrary: Low- to moderate-quality #CochraneEvidence that annual #IV cycles of alemtuzumab may reduce propor…
RT @CochraneLibrary: Low- to moderate-quality #CochraneEvidence that annual #IV cycles of alemtuzumab may reduce proportion of participants with relapses and disease progression compared with interferon beta 1a for #multiplesclerosis: https://t.co/ITCMgTg8
Low- to moderate-quality #CochraneEvidence that annual #IV cycles of alemtuzumab may reduce proportion of participants with relapses and disease progression compared with interferon beta 1a for #multiplesclerosis: https://t.co/JWKoC6V5nI #MS